Valaciclovir

DRUG16 trials

Conditions

ANCA Associated VasculitisCMV InfectionCOPDEBVEnd stage renal failureGlioblastoma (GBM)HealthyHerpes Genitalis

Phase 1

A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children

Start: 2003-01-25End: 2007-02-28Updated: 2017-09-11

Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers

CompletedNCT02226978

Boehringer IngelheimHealthy

Start: 2007-02-28Updated: 2014-08-27

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

RecruitingNCT07346144

Trogenix ltdGlioblastoma (GBM), High Grade Gliomas, Newly Diagnosed Glioblastoma +1

Start: 2026-04-21End: 2033-09-01Target: 68Updated: 2026-05-04

Phase 2

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

NCT00652184

aRigen Pharmaceuticals, Inc.Herpes Zoster, Postherpetic Neuralgia

Start: 2008-03-31End: 2009-09-30Target: 300Updated: 2008-10-07

To Rescue Cognition With Valaciclovir

CompletedNCT01364792

University Medical Center GroningenPsychosis, Schizophrenia

Start: 2011-04-30End: 2015-08-31Updated: 2016-12-01

CMV Modulation of the Immune System in ANCA-associated Vasculitis

NCT01633476

Professor Lorraine HarperANCA Associated Vasculitis, CMV Infection

Start: 2013-07-31End: 2017-09-30Updated: 2016-11-30

Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial

TerminatedNCT03699904

Belfast Health and Social Care TrustCOPD, EBV

Start: 2018-10-11End: 2020-07-01Updated: 2020-09-30

Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection

CompletedNCT04165122

Heidelberg ImmunoTherapeutics GmbHHerpes Genitalis

Start: 2019-11-15End: 2021-11-01Updated: 2022-01-18

Comparison of the efficacy and safety of valaciclovir in the prevention of transmission and treatment of intrauterine infection in pregnant women with primary cytomegalovirus infection depending on the used drug dose - the first Polish non-commercial non-inferiority clinical trial.

RecruitingCTIS2023-508643-46-00

Instytut Matki I Dzieckaprimary cytomegalovirus (CMV) infection

Start: 2024-08-02Target: 200Updated: 2025-08-29

An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T Cell Engager OM336 for Desensitization of Kidney Transplant Candidates

WithdrawnCTIS2025-523222-40-00

Medical University Of ViennaEnd stage renal failure

Target: 6Updated: 2026-05-04

Phase 3

Valaciclovir to Prevent Transmission of Herpes Simplex Virus

CompletedNCT00001649

National Institute of Allergy and Infectious Diseases (NIAID)Herpes Simplex

Start: 1997-08-31End: 2003-08-31Target: 180Updated: 2008-03-04

Phase III Study of ASP2151 in Herpes Zoster Patients

CompletedNCT01959841

Maruho Co., Ltd.Herpes Zoster

Start: 2013-08-31End: 2015-07-10Updated: 2018-11-27

A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants with X-linked Retinitis Pigmentosa

WithdrawnCTIS2024-511181-36-00

Beacon Therapeutics (USA) Inc.X-linked retinitis pigmentosa (XLRP)

Target: 5Updated: 2024-09-17

Phase 4

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

CompletedNCT00116844

GlaxoSmithKlineInfections, Herpesviridae

Start: 2005-03-29End: 2006-01-10Updated: 2018-02-12

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

CompletedNCT00158860

GlaxoSmithKlineHerpes Genitalis

Start: 2004-06-21End: 2006-07-26Updated: 2019-02-15

Unknown Phase

Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)

CompletedNCT01390857

GlaxoSmithKlineVaricella

Start: 2007-11-30End: 2010-05-31Updated: 2017-05-17

2025-10-16

Valaciclovir for Epstein-Barr Virus Suppression in Moderate-to-Severe COPD: A Randomized Double-Blind Placebo-Controlled Trial.

2023-04-014 citations

A mechanistic analysis of the effect of valaciclovir for EBV suppression on airway inflammation and microbiome in COPD

10.01 - Respiratory infections and bronchiectasis2023-03-09

Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

The Journal of Infectious Diseases2018-08-0840 citations

Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial.

2016-07-2210 citations

CD4+CD28- T-cell expansions in ANCA-associated vasculitis and association with arterial stiffness: baseline data from a randomised controlled trial.

2015-02-0112 citations

Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age.

2010-01-0124 citations

Viremia in acute herpes zoster.

2009-07-0128 citations